Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469805 | 0.90 | SRC (0.47) | PNMTCA2CA1CA9MAPK1 | |
| SCHEMBL17458779 | 0.90 | SRC (0.47) | PNMTCA2CA1CA9MAPK1 | |
| SCHEMBL1760097 | 0.82 | SRC (0.39) | PNMTPDPK1PARP1PARP10PARP11 | |
| SCHEMBL17492502 | 0.82 | PARP1 (0.38) | PNMTPDPK1PARP1PARP10PARP11 | |
| SCHEMBL12049298 | 0.78 | HTR2C (0.42) | PNMTPDPK1PARP1PARP10PARP11 | |
| SCHEMBL26656329 | 0.76 | PNMT (0.38) | PNMTCA2CA1CA9CA12 | |
| SCHEMBL10350480 | 0.74 | PNMT (0.60) | PNMTCA2CA1CA9CA6 | |
| SCHEMBL30747497 | 0.73 | F2 (0.44) | F2 | |
| SCHEMBL525390 | 0.72 | SRC (0.50) | CA2CA1CA9CA12SRC | |
| SCHEMBL7423714 | 0.72 | SRC (0.47) | PNMTCA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016025637-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2016-02-18 | — | — | WO | disclosed |
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-8623906-B2 | Carboxy isatin hydrazones and their esters as Shp2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010121212-A2 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010011666-A2 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-01-28 | — | — | WO | disclosed |
| CN-101133034-A | Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments | ESTEVE LABOR DR (ES) | 2008-02-27 | — | — | CN | disclosed |
| US-4772313-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| US-4683000-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMANY (US) | 1987-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | PTPN1, PTPN2, PTPN7 | PNMT 1189/4885CA2 2138/4885CA1 3818/4885 |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | PTPN7, PTPN3, PTPN5 | PNMT 3573/4885CA2 726/4885CA1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.